Posted By 
In a study that looks back at 20 randomized, controlled trials of the breast cancer drug tamoxifen, researchers in the Breast Cancer Trialists Collaborative Group report that 15 years after a diagnosis of estrogen receptor-positive breast cancer and 10 years after stopping the drug, women who took tamoxifen had a 1/3 lower risk of dying than those who did not take it. A lead investigator in the study stated that tamoxifen “has probably saved more lives than any other oncological drug ever.”
In addition, as has been noted in earlier studies, women who took the drug were about 40% less likely to have recurrent breast cancer. This study will be published in an upcoming issue of the journal The Lancet. More information will also be available in the Fall 2011 issue of the PBCC’s quarterly newsletter, FrontLine.
Tags: breast cancer, doctor, medical, News, women